Projected Surge in Cluster Headaches Market Growth from 2022 to 2032: Insights by DelveInsight on Eli Lilly and Company, ElectroCore INC, Winston Laboratories, AstraZeneca

Posted on
by

Projected Surge in Cluster Headaches Market Growth from 2022 to 2032: Insights by DelveInsight on Eli Lilly and Company, ElectroCore INC, Winston Laboratories, AstraZeneca
Cluster Headaches Market

(Albany, USA) DelveInsight’s “Cluster Headaches Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cluster Headaches, historical and forecasted epidemiology as well as the Cluster Headaches market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Cluster Headaches market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cluster Headaches Market Forecast

 

Some of the key facts of the Cluster Headaches Market Report: 

  • The Cluster Headaches market size was valued approximately USD 800 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • Nearly 900,000 people in the 7MM have cluster headaches on a regular basis as of 2021. The majority of cases (around 335,000) were found in the US. More than 390,000 cases originated from the EU4, including the UK
  • By 2032, it is predicted that nearly 150,000 males and 65,000 females would have cluster headaches, up from the about 140,000 males and nearly 60,000 females who had them in the United States in 2021
  • According to assessments, Germany had the biggest population of cluster headache cases among the European nations in 2021, with 99,000 instances, followed by France with 84,000 cases
  • Key Cluster Headaches Companies: Winston Laboratories, Zosano Pharma Corporation, H. Lundbeck A/S, Eli Lilly and Company, ElectroCore INC, Winston Laboratories, AstraZeneca, CCH Pharmaceuticals, and others
  • Key Cluster Headaches Therapies: Civamide, C213 Microneedle System, Eptinezumab, Galcanezumab, GammaCore, Civamide (Zucapsaicin), candesartan cilexetil, Ketamine, and others
  • The Cluster Headaches epidemiology based on gender analyzed that Cluster Headaches is more prominent in males in comparison to females
  • The Cluster Headaches market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cluster Headaches pipeline products will significantly revolutionize the Cluster Headaches market dynamics.

 

Cluster Headaches Overview

Based on variables including duration, frequency, periodicity, and other characteristics, cluster headaches are divided into episodic and chronic kinds. A minimum of two cluster episodes ranging 7 days to a year, separated by pain-free intervals lasting a month or longer, are observed in episodic cluster headaches. Attacks last longer than a year without remission in cases of chronic cluster headaches, or remissions last less than a month.

 

Get a Free sample for the Cluster Headaches Market Report 

https://www.delveinsight.com/report-store/cluster-headache-market

 

Cluster Headaches Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Cluster Headaches Epidemiology Segmentation:

The Cluster Headaches market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Cluster Headaches
  • Prevalent Cases of Cluster Headaches by severity
  • Gender-specific Prevalence of Cluster Headaches
  • Diagnosed Cases of Episodic and Chronic Cluster Headaches

 

Download the report to understand which factors are driving Cluster Headaches epidemiology trends @ Cluster Headaches Epidemiology Forecast

 

Cluster Headaches Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cluster Headaches market or expected to get launched during the study period. The analysis covers Cluster Headaches market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cluster Headaches Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Cluster Headaches Therapies and Key Companies

  • Civamide: Winston Laboratories
  • C213 Microneedle System: Zosano Pharma Corporation
  • Eptinezumab: H. Lundbeck A/S
  • Galcanezumab: Eli Lilly and Company
  • GammaCore: ElectroCore INC
  • Civamide (Zucapsaicin): Winston Laboratories
  • candesartan cilexetil: AstraZeneca
  • Ketamine: CCH Pharmaceuticals

 

Discover more about therapies set to grab major Cluster Headaches market share @ Cluster Headaches Treatment Market

 

Cluster Headaches Market Strengths

  • Cluster headaches is episodic in 80–90% of cases, with attacks occurring daily for a few weeks to a few months, followed by a gap of a few months to a few years. The chronic variety has continuous attacks for a year or longer with no symptom-free interval or a remission period that lasts for less than a month
  • Recent epidemiological studies indicate that the prevalence of Cluster headaches is about one person per 500. Thus a large cohort of patients will help ensure any new entrant make substantial gains

 

Cluster Headaches Market Opportunities

  • Despite the diagnostic challenges, the short-lasting primary headaches are important to recognize because of their excellent but highly selective response to therapy
  • Once Cluster headaches s have been accurately diagnosed, long-term treatment can be beneficial to decrease or prevent future cycles. However, as the specific underlying cause is not known, it may take some time to control the headache cycles

 

Scope of the Cluster Headaches Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Cluster Headaches Companies: Winston Laboratories, Zosano Pharma Corporation, H. Lundbeck A/S, Eli Lilly and Company, ElectroCore INC, Winston Laboratories, AstraZeneca, CCH Pharmaceuticals, and others
  • Key Cluster Headaches Therapies: Civamide, C213 Microneedle System, Eptinezumab, Galcanezumab, GammaCore, Civamide (Zucapsaicin), candesartan cilexetil, Ketamine, and others
  • Cluster Headaches Therapeutic Assessment: Cluster Headaches current marketed and Cluster Headaches emerging therapies
  • Cluster Headaches Market Dynamics: Cluster Headaches market drivers and Cluster Headaches market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Cluster Headaches Unmet Needs, KOL’s views, Analyst’s views, Cluster Headaches Market Access and Reimbursement 

 

To know more about Cluster Headaches companies working in the treatment market, visit @ Cluster Headaches Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Cluster Headaches Market Report Introduction

2. Executive Summary for Cluster Headaches

3. SWOT analysis of Cluster Headaches

4. Cluster Headaches Patient Share (%) Overview at a Glance

5. Cluster Headaches Market Overview at a Glance

6. Cluster Headaches Disease Background and Overview

7. Cluster Headaches Epidemiology and Patient Population

8. Country-Specific Patient Population of Cluster Headaches 

9. Cluster Headaches Current Treatment and Medical Practices

10. Cluster Headaches Unmet Needs

11. Cluster Headaches Emerging Therapies

12. Cluster Headaches Market Outlook

13. Country-Wise Cluster Headaches Market Analysis (2019–2032)

14. Cluster Headaches Market Access and Reimbursement of Therapies

15. Cluster Headaches Market Drivers

16. Cluster Headaches Market Barriers

17.  Cluster Headaches Appendix

18. Cluster Headaches Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services